{"id":"W2110901075","doi":"10.1186/2162-3619-3-26","title":"Activity of dalotuzumab, a selective anti-IGF1R antibody, in combination with erlotinib in unselected patients with Non-small-cell lung cancer: a phase I/II randomized trial","year":2014,"lang":"en","type":"article","venue":"Experimental Hematology and Oncology","topic":"Growth Hormone and Insulin-like Growth Factors","field":"Medicine","cited_by":32,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Merck","keywords":"Erlotinib; Medicine; Internal medicine; Randomized controlled trial; Oncology; Lung cancer; Antibody; Erlotinib Hydrochloride; Cancer; Immunology; Epidermal growth factor receptor","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002702271,0.001633401,0.002059329,0.000376539,0.0004021485,0.001069368,0.00090522,0.001342989,0.002969999],"category_scores_gemma":[0.001539192,0.0005576326,0.002035564,0.0004430032,0.001057643,0.0008401685,0.0003774203,0.002507354,0.0005782287],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001068424,"about_ca_system_score_gemma":0.001232986,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000543659,"about_ca_topic_score_gemma":0.001348143,"domain_scores_codex":[0.9991205,0.0004889713,0.00007312802,0.0001503974,0.00006523286,0.0001017343],"domain_scores_gemma":[0.9987856,0.0002696499,0.0003122492,0.00007726543,0.00007783208,0.0004773958],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9551356,0.008923055,0.003529128,0.0005252215,0.001457418,0.00008328996,0.00006767888,0.0005258656,0.005062412,0.00006851049,0.0007558651,0.02386604],"study_design_scores_gemma":[0.8951924,0.09848228,0.003595015,0.00002383111,0.0007562562,0.00009157247,0.00001673951,0.000469591,0.0005866308,0.00006580256,0.000707317,0.00001250214],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9915704,0.004502111,0.0003715831,0.0005516806,0.0001933616,0.001273156,0.0005264748,0.00004461968,0.0009666534],"genre_scores_gemma":[0.9933192,0.001969304,0.000761635,0.0007451228,0.000248087,0.001154332,0.001069052,0.00001138536,0.0007219117],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002969999,"threshold_uncertainty_score":0.01429111,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007392533454674619,"score_gpt":0.3067134082140757,"score_spread":0.2993208747594011,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}